944088-89-5

Upstream product

• 944088-85-1 tert-butyl 2-[(2-chloroethyl)[2-[(methylsulfonyl)oxy]ethyl]amino]-3,5-dinitrobenzoate 
• 87363-66-4 tert-butyl 2-chloro-3,5-dinitrobenzoate 
• 944088-72-6 tert-butyl 2-[(2-hydroxyethyl)(2-chloroethyl)amino]-3,5-dinitrobenzoate 

Downstream Products

• 1011708-22-7 methanesulfonic acid 2-[(2-chlorocarbonyl-4,6-dinitro-phenyl)-(2-chloro-ethyl)-amino]-ethyl ester 
• 851627-43-5 2-[(2-chloroethyl)-2-[[(2-hydroxyethyl)amino]carbonyl]-4,6-dinitroanilino]ethyl methanesulfonate 

Relevant academic research and scientific papers

PROCESSES OF PREPARING ASYMMETRIC DINITROBENZAMIDE MUSTARD COMPOUNDS, INTERMEDIATE COMPOUNDS USEFUL THEREIN AND PRODUCTS OBTAINED THEREFROM

The invention relates to methods of preparing compounds of formula (II) wherein Z represents -OR1 or -N(R2)R2a-, where R1 is lower alkylene (C1-C6), R2 is lower alkyl or H and R

Synthesis of asymmetric halomesylate mustards with aziridineethanol/alkali metal halides: application to an improved synthesis of the hypoxia prodrug PR-104

Aromatic asymmetric halomesylate mustards are efficiently prepared by reaction of activated aromatic chlorides with aziridineethanol/alkali metal halides, followed by mesylation of the haloalcohol. The reaction conditions are sufficiently mild to be compatible with a range of different substituents and protecting groups, including carboxylate and phosphate esters, and have been used in an improved synthesis of the anticancer bromomesylate mustard PR-104, now in clinical trials.